SEC Form 4 · accession 0001104659-17-056988
Voyager Therapeutics, Inc. · VYGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernard Ravina
Officer — Chief Medical Officer
Period of report
Jul 20, 2017
Accepted (ET)
Sep 13, 2017 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640266
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jul 20, 2017 | S | 5,490 | $10.00 | D | 49,413 | D | |
| Common StockF4,F3,F5 | Sep 11, 2017 | S | 10,980 | $14.30 | D | 32,943 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This total reflects the number of shares beneficially owned by the reporting person on July 20, 2017, following the reported transaction.
- F3This total reflects an adjustment for a clerical error on the reporting person's Form 3 wherein the number of shares beneficially owned was inadvertently overstated by 62,744 shares. Such shares were sold prior to Dr. Ravina becoming a reporting person.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.95, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- F5This total reflects the number of shares beneficially owned by the reporting person as of the date hereof, following the reported transaction and inclusive of all intervening transactions.